Congress puts big price tag on innovation in pharma
It has become expensive to develop drugs — especially for specific mutations and small patient populations. But instead of helping pharma adapt, Congress is making innovation more costly.
Most recent articles by Sander Flaum, Flaum Navigators
Focus turns to future after Right to Try Act passes
Congress has finally passed the Right to Try Act, but does it go far enough?
Drugs’ value to patients eclipsed by price tags
Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.
Will PBMs take heat for high drug prices?
PBMs began by providing a huge service to payers, but in recent years, they’ve begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
Can a nonprofit make generics great again?
Acquisitions that were applauded a few years ago, such as Teva’s purchase of Allergan’s generic business, now look like lemons.
Did Congress just kill the Orphan Drug Act?
By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first time.
We Save Lives While Our Critics Complain
In his first press conference as president-elect, Donald Trump insisted pharma was “getting away with murder” due to expensive drug prices.
Gottlieb Eyes Prices, Not Lives
It turns out the real goal is going after Washington’s favorite whipping boy — high drug prices.
Who’s Getting Rich in Healthcare?
Do you recall what President Trump tweeted right after Merck’s Kenneth Frazier resigned from his American Manufacturing Council?
AI Drug Design Could Save Lives
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.
